Portal de Periódicos da CAPES

What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?

2005; Wiley; Volume: 66; Issue: 4 Linguagem: Inglês

10.1002/ccd.20526

1522-726X

Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel,

Atrial Fibrillation Management and Outcomes

Catheterization and Cardiovascular InterventionsVolume 66, Issue 4 p. 597-597 What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Udaya S. Tantry PhD, Udaya S. Tantry PhD Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this authorKevin P. Bliden, Kevin P. Bliden Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this authorPaul A. Gurbel MD, FACC, Paul A. Gurbel MD, FACC Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this author Udaya S. Tantry PhD, Udaya S. Tantry PhD Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this authorKevin P. Bliden, Kevin P. Bliden Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this authorPaul A. Gurbel MD, FACC, Paul A. Gurbel MD, FACC Sinai Center for Thrombosis Research, Baltimore, MarylandSearch for more papers by this author First published: 05 October 2005 https://doi.org/10.1002/ccd.20526Citations: 18Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Heptinstall S, Glenn JR, May JA, Storey RF, Wilcox RG. Clopidogrel resistance. Catheter Cardiovasc Interv 2004; 63: 397–398. 2 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908–2913. 3 Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 2004; 5: 95–99. 4 Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and post-treatment platelet reactivity. Thromb Res 2005; 15: 89–94. 5 Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes KM, Tantry U. Clopidogrel Resistance and Stent Thrombosis (CREST) study. J Am Coll Cardiol 2005 (in press). 6 Gurbel PA, Bliden KP, Zaman K, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the CLEAR PLATELETS study. Circulation 2005; 111: 1153–1159. 7 Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392–1396. Citing Literature Volume66, Issue4December 2005Pages 597-597 SCAI Member Sign in ReferencesRelatedInformation